SBP solbec pharmaceuticals limited

Bank of America has re rated DNA and OSIP on the back of better...

  1. skint
    5,996 Posts.
    lightbulb Created with Sketch. 162
    clock Created with Sketch.
    13/04/05
    11:08
    Post #: 868705
    Bank of America has re rated DNA and OSIP on the back of better than expected sales of NSCLC drug Tarceva . DNA has been given a target of $62 up a further 5Billion and OSIP target is $86 up about 2Billion market cap
    Solbecs drug is shaping up as very (more?)effective against NSCLC .
    www.forbes.com/markets/2005/04/12/0412automarketscan13.html?partner=yahoo&referrer=

    SBP Price at posting: 0.0¢ Sentiment: None Disclosure: Not Held
    Likes Created with Sketch.  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

NEWS Friday's HotCopper trends: Renascor concentrate, Larvotto raise
right-arrow Created with Sketch.
NEWS What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA
right-arrow Created with Sketch.
NEWS Veteran executive to help turn Trigg into leading US-based antimony producer
right-arrow Created with Sketch.
NEWS Firetail scoops up untested land around Excelsior – including juicy mineralisation target
right-arrow Created with Sketch.
NEWS Harness the power of Australia’s leading investor community
right-arrow Created with Sketch.
NEWS Access the Latest ASX news daily on HotCopper
right-arrow Created with Sketch.
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.